AN2 Therapeutics, Inc. (NASDAQ: ANTX) is a Healthcare company (Biotechnology) with a market capitalization of $161M. The Maz Rating grades it against the other companies in its sector.
AN2 Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.23, AN2 Therapeutics, Inc. trades at 2.6x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -48.7%, return on invested capital of -49.5% and a free cash flow yield of -18.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 10.48. Over the past 52 weeks the share price ranged from $1.00 to $7.19, with a beta of -0.94.
AN2 Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 5 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, AN2 Therapeutics, Inc. (ANTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 36.9% / 30% · Interest income / Revenue 71300000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 29.6% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 71300000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 29.6% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 71300000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.4% / 33.33% · Receivables / Avg Assets (4Q) 0.19% / 33.33% · Interest income / Revenue 71300000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 78.6% / 33.33% · (Cash+Recv) / Total Assets 78.6% / 33.33% · Interest income / Revenue 71300000.0% / 5% | Fail |
No. As of September 2026, AN2 Therapeutics, Inc. (ANTX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. AN2 Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 71300000.0% of each dividend: AN2 Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.